The current study reports the development of a novel biofluid sampler (BFS) which is capable of sampling and sample preparation of whole blood without converting it into plasma or serum. The sampler can retain a whole blood sample from 10 to 1000 µL. Although the device shares the same working principle of dried blood spot (DBS) cards, it eliminates most of the technological shortcomings of DBS cards such as low maximum sample volume (~50 µL), sample inhomogeneity due to haematocrit, and poor physical adsorption driven analyte retention by incorporating sol-gel derived high efficiency, multi-functional sorbents on cellulose fabric substrate. The performance of BFS was tested via "Mail-in-Analysis" using three non-steroidal anti-inflammatory drugs (NSAIDs, ketoprofen, carprofen and diclofenac) as the test compounds. Human whole blood samples were fortified with the test compounds and sampled on conventional DBS cards and biofluid samplers (BFSs) in the USA. After drying the blood samples at room temperature, the samples were shipped to Italy for chromatographic analysis. The analytes were back-extracted from the DBS cards and BFSs using methanol and subsequently analysed using a short Symmetry C18 column (75 × 4.6 mm, 3.5 µm). Acetonitrile (ACN) and PBS (30 mM; pH = 2.5) were used as the mobile phases and the elution was performed under isocratic conditions. Compared to the classical dried blood spot cards (DBS), BFSs offer better performance in retaining the selected NSAIDs under conventional postal shipment. By substantially expanding the sampling capacity, eliminating most of the shortcomings of classical DBS cards and exploiting the better materials properties of sol-gel based functional sorbents, BFSs offer a new and profoundly simplified approach for whole blood sampling and analysis and is expected to change the current practice of blood analysis, allowing accurate quantitative analyses either in a local laboratory (on site) or using mail-in-analysis (off site) without compromising the quality of bioanalytical data.

中文翻译：

---

生物流体采样器：一种用于全血样品邮件分析的新途径。

当前的研究报道了新型生物流体采样器（BFS）的开发，该采样器能够对全血进行采样和样品制备，而无需将其转换为血浆或血清。采样器可以保留10至1000 µL的全血样品。尽管该设备具有与干血斑（DBS）卡相同的工作原理，但它消除了DBS卡的大多数技术缺陷，例如，最大样本量低（〜50 µL），由于血细胞比容导致的样本不均匀以及不良的物理吸附驱动通过在纤维素织物基质上掺入溶胶-凝胶衍生的高效多功能吸附剂来保留分析物。通过使用三种非甾体抗炎药（NSAID，酮洛芬，卡洛芬和双氯芬酸）作为测试化合物，通过“邮件分析”测试了BFS的性能。用测试化合物强化人类全血样品，并在美国的常规DBS卡和生物流体采样器（BFS）上进行采样。在室温下干燥血液样本后，将样本运送到意大利进行色谱分析。使用甲醇从DBS卡和BFS中反萃取分析物，然后使用短Symmetry C18色谱柱（75×4.6 mm，3.5 µm）进行分析。将乙腈（ACN）和PBS（30 mM； pH = 2.5）用作流动相，并在等度条件下进行洗脱。与传统的干血点卡（DBS）相比，BFS在保留常规邮政运输中选择的NSAID方面具有更好的性能。通过大幅扩展采样容量，